Dr Shadman on Zanubrutinib in CLL/SLL Intolerant to Prior BTK Inhibitors
October 8th 2023Mazyar Shadman, MD, MPH, discusses preliminary long-term findings from the evaluation of zanubrutinib in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were intolerant to ibrutinib and/or acalabrutinib.
Read More
Dr. Shadman on the Efficacy and Safety of Zanubrutinib in CLL
September 7th 2023Mazyar Shadman, MD, MPH, discusses the efficacy and safety of zanubrutinib in chronic lymphocytic leukemia, as well as data derived from the agents use which supports the regulatory approval of zanubrutinib in this patient population.
Read More
Dr. Shadman on the Exploration of the CAR T-Cell Therapy MB-106 in NHL/CLL
August 8th 2022Mazyar Shadman, MD, MPH, discusses the exploration of MB-106, a third-generation CD20-targeted autologous CAR T-cell therapy, in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Read More
Dr. Shadman on Methods Utilized to Evaluate MB-106 in B-NHL and CLL
January 12th 2022Mazyar Shadman, MD, MPH, discusses the methods utilized in an ongoing phase 1/2 trial evaluating MB-106, an investigational CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Read More
Dr. Shadman on the Safety Profile of a CD20-Directed CAR T-Cell Therapy in B-NHL and CLL
December 22nd 2021Mazyar Shadman, MD, MPH, discusses the safety profile of MB-106, a third-generation, CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Read More